Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

7.00USD
20 Apr 2018
Change (% chg)

$-0.05 (-0.71%)
Prev Close
$7.05
Open
$7.05
Day's High
$7.10
Day's Low
$6.90
Volume
6,075
Avg. Vol
16,534
52-wk High
$11.90
52-wk Low
$3.80

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $136.71
Shares Outstanding(Mil.): 18.60
Dividend: --
Yield (%): --

Financials

  ALDX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.47 -- --
ROI: -72.27 1.58 14.38
ROE: -75.02 2.41 16.07

BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs

* ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES

27 Feb 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Dry Eye Disease Phase 2B Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Aldeyra Therapeutics reports Q3 loss per share of $0.32

* Aldeyra Therapeutics announces third quarter 2017 financial results

09 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.66 -0.89
Novartis AG (NOVN.S) CHF76.08 -1.20
Pfizer Inc. (PFE.N) $36.63 +0.10
AbbVie Inc (ABBV.N) $92.60 -0.41
Amgen, Inc. (AMGN.OQ) $171.56 -1.37
Bristol-Myers Squibb Co (BMY.N) $51.17 -0.44
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 --
UCB SA (UCB.BR) €65.28 -0.34

Earnings vs. Estimates